<DOC>
	<DOCNO>NCT02199886</DOCNO>
	<brief_summary>Study assess toxicity , pharmacokinetics , biodistribution image characteristic associate increase dos 131I-BIBH 1 , compare uptake 131I-BIBH 1 tumour normal tissue patient non-small cell lung cancer measure human anti-human antibody ( HAHA ) concentration .</brief_summary>
	<brief_title>Dose-escalation Study BIBH 1 Patients With Non-small Cell Lung Cancer Scheduled Surgical Resection</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically confirm primary secondary advance nonsmall cell lung cancer Eligible lung biopsy schedule surgery would provide biopsy material Karnofsky performance status ≥ 70 Expected survival ≥ 3 month Greater equal 18 year age Absolute granulocyte count ≥ 2.5 x 10**9/L Lymphocyte count &gt; 0.7 x 10**9/L Platelet count ≥ 100 x 10**9/L Serum Creatinine ≤ 2.0 mg/dl ( 0.20 mmol/L ) Alanine aminotransferase/aspartate aminotransferase ( ALT/AST ) ≤ 3x upper limit normal Total bilirubin &lt; 2 mg/dl 34µmol ( SI unit equivalent ) Ability provide write informed consent Active metastatic disease central nervous system , exhibit new enlarge lesion CT MRI scan within 3 month treatment ( i.e. , surgery radiotherapy ) brain metastasis Exposure investigational agent within four week BIBH 1 infusion Patients fully recover surgery . Because potential binding BIBH 1 heal scar , patient incomplete heal incision site , evidence incomplete granulation , infection localize edema exclude Chemotherapy immunotherapy within four week precede entry ( six week nitrsoureas and/or mitomycinC . ) Previous administration murine , chimeric humanise measurement and/or antibody fragment Serious illness : e.g. , active infection require antibiotic , bleed disorder disease consider investigator potential interfering obtain accurate result study Women breastfeed pregnant Men woman childbearing potential unwilling utilize medically acceptable method contraception Previous participation study Patients autoimmune disease hypertopic skin condition possibly overexpress Fibroblast Activation Protein may target antibody . These disease include active inflammatory arthritis , cirrhosis keloid . Patients unstable angina pectoris . Patients prescribed medication control angina pectoris must fix dose least 1 month prior screen eligible trial . Patients experience myocardial infarction within 3 month Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>